Spondyloarthritis

Ixekizumab Provides Sustained and Clinically Meaningful Improvement in Active Radiographic Axial Spondyloarthritis

Researchers investigated the efficacy and safety of ixekizumab for up to 52 weeks in patients with active radiographic axial spondyloarthritis who were biologic disease-modifying antirheumatic drug-naive or tumor necrosis factor inhibitor-experienced.

Syndesmophyte Presence Predictive of Further Structural Damage Development in Early Axial Spondyloarthritis

Researchers analyzed the progression of spinal radiographic damage in patients with early axial spondyloarthritis.

Clinical Disease Activity Measures Associated With Trabecular Bone Loss in Axial Spondyloarthritis

Researchers evaluated the association between trabecular bone loss and disease activity measures in patients with axial spondyloarthritis.

ASAS Releases Quality Standards to Improve Healthcare of Patients With Axial Spondyloarthritis

The Assessment of SpondyloArthritis International Society sought to develop a global set of quality standards to help improve healthcare quality for adult patients with axial spondyloarthritis.

Comorbid Fibromyalgia Reduces Effectiveness of Biologics in Psoriatic Arthritis

Researchers evaluated the effect of fibromyalgia on the clinical outcomes of biologics in patients with psoriatic arthritis.

Ixekizumab Superior to Adalimumab in Joint, Skin Improvement in Psoriatic Arthritis

Ixekizumab demonstrated superiority to adalimumab in achieving simultaneous joint and skin improvement in biologic-naive patients with active psoriatic arthritis, according to data from the phase 3b/4 SPIRIT Head-to-Head (H2H) study.

Ixekizumab Superior to Placebo in Improving Symptoms, Inflammation in Nonradiographic Axial Spondyloarthritis

In a phase 3 study, researchers assessed the efficacy and safety of ixekizumab in patients with active nonradiographic axial spondyloarthritis.

TNF Inhibitors Reduce Radiographic Progression in Ankylosing Spondylitis

Tumor necrosis factor inhibitors slow radiologic progression when compared to other drug classes in ankylosing spondylitis.

Contextual, Disease-Related Factors Linked to Depressive Symptoms in Ankylosing Spondylitis

Researchers aimed to identify factors related to depressive symptoms in ankylosing spondylitis and comprehend their underlying associations.

Improvement in Joint Symptoms, Pain With Tildrakizumab-asmn in Psoriatic Arthritis

Tildrakizumab-asmn demonstrated significant improvements to swollen and tender joint counts and pain in patients with active psoriatic arthritis (PsA), according to phase 2b interim results.